Lucid Diagnostics director purchases 100,000 LUCD shares at ~$1.02

Rhea-AI Filing Summary

Lucid Diagnostics director Dennis Matheis reported a purchase of company common stock. The Form 4 discloses a purchase of 100,000 shares on 08/20/2025 at a weighted-average price of $1.0184 per share, with transaction prices ranging from $1.0085 to $1.0286. After the purchase, the reporting person beneficially owned 665,443 shares. The filing indicates the reporting person is a director and the Form 4 was filed by one reporting person. The reporting person authorized Michael A. Gordon to sign the Form 4 by power of attorney.

Positive

• Director purchase reported, which can signal insider alignment with shareholders
• Clear disclosure of weighted-average price and price range for the transactions

Negative

• No context provided on total outstanding shares or prior insider activity to assess materiality
• Purchase size may be immaterial to shareholders absent additional information on company float

Insights

Corporate Governance Expert

TL;DR: A director purchased shares at low single-digit prices, modestly increasing insider stake; routine corporate governance disclosure.

The reported purchase is a standard disclosure under Section 16. A director acquiring 100,000 shares increases insider alignment with shareholders and is properly reported with price range detail and a POA signature. The filing does not disclose intent, source of funds, or any plan-based trading arrangement. Without total outstanding shares or prior recent insider activity, the governance implications are limited to signaling alignment rather than indicating material corporate change.

Securities Analyst

TL;DR: Insider buy of 100,000 shares at ~$1.02 is a factual data point but likely not material absent context on share count or market impact.

The transaction price range and weighted-average price are clearly stated, and post-transaction beneficial ownership is provided. From a market-impact perspective, the disclosed purchase size appears modest unless the company's float is very small. The filing contains no derivative activity or dispositions and adheres to disclosure requirements; it is a neutral data point for valuation models unless combined with other insider trends.

Insider Trade Summary

Net Buyer: 100,000 shares ($101,840)

Net Buy 1 txn

Insider Matheis Dennis

Role Director

Bought 100,000 shs ($102K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	100,000	$1.0184	$102K

Holdings After Transaction: Common Stock — 665,443 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 08/22/2025 - 05:17 PM Learn about SEC filing dates

FAQ

What transaction did Lucid Diagnostics (LUCD) insider Dennis Matheis report?

The Form 4 reports a purchase of 100,000 common shares on 08/20/2025.

At what price were the LUCD shares purchased in the Form 4?

The weighted-average price was $1.0184 per share, with individual trades between $1.0085 and $1.0286.

How many LUCD shares does the reporting person own after the transaction?

After the purchase the reporting person beneficially owned 665,443 shares.

What is the reporting person’s relationship to Lucid Diagnostics?

The filing indicates the reporting person is a director of Lucid Diagnostics.

Was the Form 4 signed by the reporting person?

The Form 4 was signed under power of attorney by Michael A. Gordon on behalf of the reporting person.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Matheis Dennis

(Last) (First) (Middle)

360 MADISON AVENUE, 25TH FLOOR

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lucid Diagnostics Inc. [ LUCD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/20/2025		P		100,000	A	$1.0184(1)	665,443	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.0085 to $1.0286. inclusive. The reporting person undertakes to provide to Lucid Diagnostics Inc., any security holder of Lucid Diagnostics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

	/s/ Michael A. Gordon, by power of attorney	08/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.